

Peter M Izmirly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/212793/publications.pdf>

Version: 2024-02-01

90
papers

6,712
citations

109137

35
h-index

79541

73
g-index

95
all docs

95
docs citations

95
times ranked

6556
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. <i>Arthritis and Rheumatology</i> , 2022, 74, 284-294.	2.9	103
2	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. <i>Rheumatology</i> , 2022, 61, 4335-4343.	0.9	6
3	Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 829-839.	2.9	38
4	COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study. <i>JAAD International</i> , 2022, 8, 31-33.	1.1	2
5	Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. <i>Lancet Rheumatology</i> , The, 2022, 4, e384-e387.	2.2	27
6	High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis. <i>Journal of Rheumatology</i> , 2022, 49, 388-397.	1.0	11
7	Gut dysbiosis and the clinical spectrum in anti-Ro positive mothers of children with neonatal lupus. <i>Gut Microbes</i> , 2022, 14, .	4.3	6
8	Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. <i>Lancet Rheumatology</i> , The, 2022, 4, e582-e585.	2.2	9
9	Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment. , 2021, , 507-519.		1
10	Passively acquired lupus in the fetus and neonate. , 2021, , 325-363.		0
11	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
12	Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021, 8, e000475.	1.1	10
13	Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	61
14	Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. <i>Arthritis and Rheumatology</i> , 2021, 73, 991-996.	2.9	114
15	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1339-1344.	0.5	202
16	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. <i>Lancet Rheumatology</i> , The, 2021, 3, e585-e594.	2.2	18
17	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. <i>Lupus Science and Medicine</i> , 2021, 8, e000522.	1.1	5
18	Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19. <i>Life Science Alliance</i> , 2021, 4, e202101180.	1.3	15

#	ARTICLE	IF	CITATIONS
19	511â€¦Disease flares in lupus are concordant with <i>Ruminococcus Blautia Gnavus</i> blooms arising within unstable gut microbiota communities. , 2021, , .		0
20	901â€¦Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. , 2021, , .		0
21	1118â€¦Incidence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the centers for disease control and prevention national lupus registries. , 2021, , .		0
22	Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. <i>Lupus Science and Medicine</i> , 2021, 8, e000614.	1.1	17
23	Autoimmune-mediated congenital heart block. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 64, 41-51.	1.4	38
24	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. <i>Arthritis Care and Research</i> , 2020, 72, 233-242.	1.5	17
25	Systemic Autoimmune Disease Among Adults Exposed to the September 11, 2001 Terrorist Attack. <i>Arthritis and Rheumatology</i> , 2020, 72, 849-859.	2.9	29
26	Factors associated with long-term cardiac dysfunction in neonatal lupus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 217-224.	0.5	6
27	Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. <i>Journal of the American College of Cardiology</i> , 2020, 76, 292-302.	1.2	97
28	Leveraging the United States Epicenter to Provide Insights on COVIDâ€“19 in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 1971-1980.	2.9	51
29	COVIDâ€“19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Diseaseâ€“Modifying Antirheumatic Drugs on Clinical Outcomes. <i>Arthritis and Rheumatology</i> , 2020, 72, 1981-1989.	2.9	92
30	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
31	O8â€¦Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
32	Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008686.	2.1	16
33	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. <i>Arthritis Research and Therapy</i> , 2020, 22, 191.	1.6	21
34	Sex Differences in Systemic Lupus Erythematosus. <i>Mayo Clinic Proceedings</i> , 2020, 95, 384-394.	1.4	83
35	Covid-19 in Immune-Mediated Inflammatory Diseases â€“ Case Series from New York. <i>New England Journal of Medicine</i> , 2020, 383, 85-88.	13.9	377
36	Hydroxychloroquine Toxicity. <i>Journal of Clinical Rheumatology</i> , 2020, Publish Ahead of Print, .	0.5	1

#	ARTICLE	IF	CITATIONS
37	Integrated urine proteomics and renal single-cell genomics identify an IFN- β response gradient in lupus nephritis. JCI Insight, 2020, 5, .	2.3	57
38	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	2.3	30
39	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. Arthritis Care and Research, 2019, 71, 949-960.	1.5	38
40	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.5	759
41	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	2.9	1,098
42	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Science and Medicine, 2019, 6, e000344.	1.1	22
43	Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nature Immunology, 2019, 20, 915-927.	7.0	275
44	Pregnancy outcomes in mixed connective tissue disease: a multicentre study. Rheumatology, 2019, 58, 2000-2008.	0.9	10
45	194â€¦Transcriptome analysis of skin fibroblasts derived from lupus nephritis patients demonstrates fibrotic and interferon-related cellular biomarkers. , 2019, , .		0
46	273â€¦Safety of research cores obtained from clinically indicated biopsies in the accelerating medicines partnership network. , 2019, , .		0
47	300â€¦Insights from single-cell RNA sequencing of skin and kidney in lupus nephritis. , 2019, , .		0
48	64â€¦ANA by indirect immunofluorescence alone rare in SLE and clinical phenotype of patients with ANA plus lupus associated antibodies is different than ANA alone. , 2019, , .		0
49	SLE clinical trials: impact of missing data on estimating treatment effects. Lupus Science and Medicine, 2019, 6, e000348.	1.1	7
50	SLE: reconciling heterogeneity. Lupus Science and Medicine, 2019, 6, e000280.	1.1	23
51	Neonatal Lupus. , 2019, , 486-498.		1
52	Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Seminars in Arthritis and Rheumatism, 2018, 47, 545-551.	1.6	47
53	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2018, 103, 1074-1082.	2.3	48
54	CS-31â€¦Safety of hydroxychloroquine withdrawal in older adults with systemic lupus erythematosus. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
55	CS-04â€¦Associated factors of long-term cardiac dysfunction in a longitudinal cohort of neonatal lupus. , 2018, , .		0
56	Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1742-1749.	0.5	40
57	Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials. <i>Lupus Science and Medicine</i> , 2018, 5, e000266.	1.1	6
58	A protective Langerhans cellâ€“keratinocyte axis that is dysfunctional in photosensitivity. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	48
59	Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. <i>Current Opinion in Rheumatology</i> , 2017, 29, 467-472.	2.0	39
60	Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. <i>Arthritis and Rheumatology</i> , 2017, 69, 785-790.	2.9	10
61	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. <i>Arthritis and Rheumatology</i> , 2017, 69, 2006-2017.	2.9	126
62	Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. <i>Autoimmunity Reviews</i> , 2017, 16, 980-983.	2.5	25
63	Validation of Systemic Lupus Erythematosus Diagnosis as the Primary Cause of Renal Failure in the US Renal Data System. <i>Arthritis Care and Research</i> , 2017, 69, 599-604.	1.5	9
64	Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. <i>JCI Insight</i> , 2017, 2, .	2.3	164
65	No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 857-859.	0.4	4
66	Neonatal Lupus. , 2016, , 451-461.		1
67	In search of an antibody specificity highly predictive of congenital heart block. <i>Lupus Science and Medicine</i> , 2016, 3, e000154.	1.1	7
68	Mortality in Systemic Lupus Erythematosus: an Updated Review. <i>Current Rheumatology Reports</i> , 2016, 18, 21.	2.1	118
69	Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1161-1165.	0.5	81
70	Early diagnosis of primary Sjögrenâ€™s syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 137-156.	1.3	118
71	Rapid aneurysm growth and rupture in systemic lupus erythematosus. , 2015, 6, 9.		15
72	The clinical spectrum of autoimmune congenital heart block. <i>Nature Reviews Rheumatology</i> , 2015, 11, 301-312.	3.5	209

#	ARTICLE	IF	CITATIONS
73	Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro-associated Cardiac Neonatal Lupus. <i>Journal of the American College of Cardiology</i> , 2015, 66, 930-939.	1.2	32
74	Prevention and Treatment In Utero of Autoimmune-Associated Congenital Heart Block. <i>Cardiology in Review</i> , 2014, 22, 263-267.	0.6	90
75	Neonatal Lupus. , 2014, , 251-272.		3
76	Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials." by Gleicher N, Elkayam U, <i>Autoimmun Rev.</i> 2013 Sep;12(11):1039-45. <i>Autoimmunity Reviews</i> , 2014, 13, 70-72.	2.5	7
77	Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. <i>Rheumatology</i> , 2012, 51, 1086-1092.	0.9	96
78	Neonatal lupus. <i>Current Opinion in Rheumatology</i> , 2012, 24, 466-472.	2.0	44
79	Dysregulation of the Microvasculature in Nonlesional Non-Sun-exposed Skin of Patients with Lupus Nephritis. <i>Journal of Rheumatology</i> , 2012, 39, 510-515.	1.0	6
80	Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody-associated Cardiac Manifestations of Neonatal Lupus. <i>Circulation</i> , 2012, 126, 76-82.	1.6	363
81	Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. <i>Arthritis Care and Research</i> , 2012, 64, 1373-1381.	1.5	39
82	Maternal and Fetal Factors Associated With Mortality and Morbidity in a Multi-racial/Ethnic Registry of Anti-SSA/Ro-associated Cardiac Neonatal Lupus. <i>Circulation</i> , 2011, 124, 1927-1935.	1.6	257
83	Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 1138-1146.	6.7	211
84	Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. <i>Arthritis and Rheumatism</i> , 2010, 62, 1153-1157.	6.7	119
85	Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1827-1830.	0.5	192
86	Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. <i>Arthritis and Rheumatism</i> , 2009, 60, 3091-3097.	6.7	135
87	Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. <i>Rheumatology</i> , 2008, 48, 513-519.	0.9	24
88	Neonatal Lupus Syndromes. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 267-285.	0.8	84
89	Evaluation of the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population Based Registry. <i>Arthritis Care and Research</i> , 0, , .	1.5	2
90	To Be or Not to Be Treated: That Is the Question in Managing a Fetus With Cardiac Injury Exposed to Anti-SSA/Ro. <i>Journal of the American Heart Association</i> , 0, , .	1.6	1